Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 10/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PTPN7 | P35236 | 2/20 | 0.40 |
| ▸ | DUSP3 | P51452 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13165641 | 0.94 | EPHX2 (0.45) | EPHX2ALDH1A1SMN1; SMN2TSHRP2RX7 | |
| SCHEMBL13166053 | 0.91 | EPHX2 (0.44) | EPHX2ALDH1A1SMN1; SMN2TSHRP2RX7 | |
| SCHEMBL10121227 | 0.89 | EPHX2 (0.44) | EPHX2ALDH1A1P2RX7L3MBTL1PTPN7 | |
| SCHEMBL12238932 | 0.89 | L3MBTL1 (0.43) | EPHX2ALDH1A1SMN1; SMN2P2RX7POLB | |
| SCHEMBL756146 | 0.88 | EPHX2 (0.61) | EPHX2ALDH1A1SMN1; SMN2TSHRPOLB | |
| SCHEMBL13165635 | 0.88 | EPHX2 (0.46) | EPHX2ALDH1A1SMN1; SMN2TSHRPOLB | |
| SCHEMBL765666 | 0.88 | BDKRB1 (0.43) | EPHX2ALDH1A1SMN1; SMN2P2RX7POLB | |
| SCHEMBL12238930 | 0.87 | EPHX2 (0.41) | EPHX2ALDH1A1P2RX7POLBL3MBTL1 | |
| SCHEMBL764477 | 0.87 | L3MBTL1 (0.41) | EPHX2ALDH1A1SMN1; SMN2P2RX7POLB | |
| SCHEMBL12238928 | 0.86 | L3MBTL1 (0.41) | EPHX2ALDH1A1SMN1; SMN2P2RX7POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8916589-B2 | Bradykinin B1-antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-23 | — | — | US | disclosed |
| US-8916589-B2 | Bradykinin B1-antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-23 | — | — | US | disclosed |
| EP-2188254-B1 | NOVEL BRADYKININ B1-ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2012-03-21 | — | — | EP | disclosed |
| US-20110263626-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| US-20110263626-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| WO-2009027450-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263626-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | BDKRB1, BDKRB2, EDNRB | EPHX2 872/4885ALDH1A1 2920/4885SMN1; SMN2 4189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.